Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma

By Vaishampayan Ulka   Heilbrun Lance   Shields Anthony   Lawhorn-Crews Jawana   Baranowski Karen   Smith Daryn   Flaherty Lawrence  

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 69-75

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

By Vuky Jacqueline   Isacson Christina   Fotoohi Mehran   Cruz Jason   Otero Henry   Picozzi Vincent   Malpass Thomas   Aboulafia David   Jacobs Andrew  

Investigational New Drugs, Vol. 24, Iss. 1, 2006-01 ,pp. : 85-88

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma

By Huie Michael   Oettel Kurt   Ummersen Lynn   Kim Kyung   Zhang Yulin   Staab Mary   Horvath Dottie   Marnocha Rebecca   Douglas Jeff   Drezen Amy   Alberti Dona   Wilding George  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 255-260

Springer Publishing Company

Access to resources Recommend Favorite

A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma

By Peterson Amy   Harlin Helena   Karrison Theodore   Vogelzang Nicholas   Knost James   Kugler John   Lester Eric   Vokes Everett   Gajewski Thomas   Stadler Walter  

Investigational New Drugs, Vol. 24, Iss. 2, 2006-03 ,pp. : 141-149

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of nolatrexed dihydrochloride [Thymitaq^TM, AG 337] in patients with advanced hepatocellular carcinoma

By Jhawer Minaxi   Rosen Lee   Dancey Janet   Hochster Howard   Hamburg Solomon   Tempero Margaret   Clendeninn Neil   Mani Sridhar  

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 85-94

Springer Publishing Company

Access to resources Recommend Favorite